Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-12-008262
Filing Date
2012-02-14
Accepted
2012-02-14 11:04:45
Documents
11
Period of Report
2011-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q v302016_10q.htm 10-Q 264981
2 CERTIFICATION v302016_ex31-1.htm EX-31.1 9137
3 CERTIFICATION v302016_ex31-2.htm EX-31.2 9018
4 CERTIFICATION v302016_ex32-1.htm EX-32.1 4536
5 CERTIFICATION v302016_ex32-2.htm EX-32.2 4433
  Complete submission text file 0001144204-12-008262.txt   1459351

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT tglp-20111231.xml EX-101.INS 122855
7 XBRL TAXONOMY EXTENSION SCHEMA tglp-20111231.xsd EX-101.SCH 13500
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tglp-20111231_cal.xml EX-101.CAL 33923
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tglp-20111231_def.xml EX-101.DEF 80643
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE tglp-20111231_lab.xml EX-101.LAB 100125
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tglp-20111231_pre.xml EX-101.PRE 96742
Mailing Address 125 MAIDEN LANE, SUITE 309 NEW YORK NY 10038
Business Address 125 MAIDEN LANE, SUITE 309 NEW YORK NY 10038 212-797-9877
Tongli Pharmaceuticals (USA), Inc. (Filer) CIK: 0001052284 (see all company filings)

EIN.: 841090791 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-52954 | Film No.: 12604227
SIC: 2834 Pharmaceutical Preparations